Park Avenue Securities LLC Buys 5,820 Shares of Novartis AG $NVS

Park Avenue Securities LLC grew its stake in shares of Novartis AG (NYSE:NVS) by 13.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,735 shares of the company’s stock after purchasing an additional 5,820 shares during the quarter. Park Avenue Securities LLC’s holdings in Novartis were worth $7,091,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. apricus wealth LLC raised its stake in Novartis by 4.4% during the 3rd quarter. apricus wealth LLC now owns 25,943 shares of the company’s stock worth $3,699,000 after acquiring an additional 1,105 shares in the last quarter. Miller Howard Investments Inc. NY purchased a new stake in Novartis in the third quarter valued at $32,737,000. Leo Wealth LLC acquired a new position in Novartis in the third quarter valued at $1,386,000. Apollon Wealth Management LLC boosted its stake in Novartis by 30.2% in the third quarter. Apollon Wealth Management LLC now owns 13,072 shares of the company’s stock valued at $1,864,000 after acquiring an additional 3,035 shares in the last quarter. Finally, Brucke Financial Inc. boosted its stake in Novartis by 25.2% in the third quarter. Brucke Financial Inc. now owns 3,755 shares of the company’s stock valued at $535,000 after acquiring an additional 756 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Raised 2026 core-profit outlook: Novartis increased its forecast for full-year core operating income, citing sales growth and productivity improvements. Management also maintained its outlook for full-year sales growth. Novartis Q3 Profit Sinks 70% Despite Sales Growth; Lifts FY26 Core Income View, Backs Sales Outlook
• Positive Sentiment: Quarterly earnings beat estimates: Novartis reported adjusted earnings of $2.46 per share, above the $2.25 consensus, while revenue increased year over year. Growth from Kisqali, Kesimpta and Scemblix helped offset generic-drug pressure. NVS Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
• Neutral Sentiment: Analyst estimates remain broadly constructive: Erste Group Bank made only small changes to its forecasts, trimming its 2026 EPS estimate to $9.16 from $9.24 while raising its 2027 estimate to $9.81 from $9.80. Both remain above the broader current-year consensus of $8.91.
• Negative Sentiment: Reported profit fell sharply: Third-quarter net profit declined about 70%, largely because of a roughly $1.9 billion impairment charge and higher expenses. Although the charge is nonrecurring, it weakened headline results and may be contributing to investor caution. Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
• Negative Sentiment: Execution concerns remain: Kisqali, one of Novartis’ key growth medicines, reportedly fell short of expectations, while generic competition continues to erode sales. Recent clinical-trial setbacks also add uncertainty around the company’s pipeline and future growth.

Novartis Stock Down 0.6%

Shares of NYSE:NVS opened at $155.91 on Thursday. The stock has a market cap of $297.49 billion, a P/E ratio of 23.52, a P/E/G ratio of 2.74 and a beta of 0.41. The firm has a fifty day moving average price of $148.31 and a 200 day moving average price of $151.61. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.53 billion. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Novartis’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.25 earnings per share. Sell-side analysts predict that Novartis AG will post 8.91 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NVS shares. Bank of America reiterated a “buy” rating on shares of Novartis in a research report on Tuesday, September 8th. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Wednesday. Jefferies Financial Group restated a “neutral” rating on shares of Novartis in a research note on Thursday, July 23rd. Sanford C. Bernstein reaffirmed a “neutral” rating on shares of Novartis in a research report on Wednesday, July 22nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $163.00 price target on shares of Novartis in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $152.25.

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.